Welcome to our dedicated page for Biolargo news (Ticker: BLGO), a resource for investors and traders seeking the latest updates and insights on Biolargo stock.
BioLargo, Inc. develops and commercializes sustainable technologies across cleantech, environmental engineering, water treatment and life sciences. Company updates commonly cover its Aqueous Electrostatic Concentrator, a PFAS treatment technology designed to remove and collect per- and polyfluoroalkyl substances from liquid streams, as well as engineering services and project work in water, wastewater, remediation and minerals processing.
BioLargo news also follows subsidiary activity, including Clyra Medical Technologies and its FDA-cleared wound care products based on Copper-Iodine Complex Technology, distribution partnerships for ViaCLYR, investor communications, annual operating results, and commercialization updates across medical, environmental and battery-related business lines.
BioLargo (BLGO) will host a public townhall, Q2 2026 earnings results webcast, and conference call on Thursday, September 10, 2026, at 1:00 pm Pacific / 4:00 pm Eastern to review financial results for the three months ended June 30, 2026 and discuss recent milestones in an extended Q&A format.
Participants can join via webcast at https://www.webcaster5.com/Webcast/Page/2448/54527 or by teleconference using domestic number 888-506-0062 or international number +1-973-528-0011 with access code 543643. A teleconference replay will be available through Thursday, September 24, 2026 at 877-481-4010 (domestic) or 919-882-2331 (international) with passcode 54527. Investors are encouraged to submit questions in advance via the BioLargo Shareholder Discord and access replay materials on the company’s investor relations website.
BioLargo (BLGO) announced that subsidiary Clyra Medical Technologies has signed an exclusive purchasing and reseller agreement with Spartan Medical to distribute its FDA 510(k)-cleared ViaCLYR™ wound irrigation solution to U.S. government healthcare facilities worldwide.
The deal creates Clyra’s third distribution channel, expanding beyond its existing U.S. commercial distributor Advanced Solutions and an international agreement with Al Hikma covering 18 countries. ViaCLYR, powered by the Clyrasept™ Copper-Iodine Complex Solution (CICS), is described as a broad-spectrum antimicrobial optimized for speed, efficacy, persistence, and biocompatibility. In clinical tests, it killed 99.9999% of 18 pathogens within one minute and provided up to 72 hours of antimicrobial management without reapplication, while remaining non-cytotoxic.
ViaCLYR is now listed on the Defense Logistics Agency’s ECAT system and is available to VA and DoD facilities, the Federal Bureau of Prisons, Indian Health Service, other federal healthcare facilities, and certain civilian hospitals under VA-funded contracts.
BioLargo (OTCQX:BLGO) announced that President and CEO Dennis P. Calvert will present at the inaugural Nasdaq / LD Micro Summit on Wednesday, September 9, 2026, at Nasdaq's San Francisco headquarters. The event will host about 25 public companies presenting to institutional investors.
Each company, including BioLargo, is scheduled for a 15-minute presentation followed by a 15-minute breakout session for Q&A with management. Investors can also request one-on-one meetings with Calvert through conference representatives or by emailing BioLargo's investor relations contact.
BioLargo (OTCQX:BLGO) announced it will participate in Gabelli Funds' 4th Annual PFAS Symposium on September 24, 2026, in New York City. Former U.S. EPA senior executive Sally Gutierrez, a board member of BioLargo subsidiary BEST, will represent the company.
According to BioLargo, its PFAS solution is the patented Aqueous Electrostatic Concentrator (AEC), commercialized through BEST. A commercial reference installation at the Lake Stockholm water facility in New Jersey has operated for more than six months and is monitored under a 12‑month program by the New Jersey Department of Environmental Protection.
BioLargo (OTCQX: BLGO) reported second quarter 2026 revenue of $1,248,000, up 12% sequentially from Q1 2026 but down 55% from Q2 2025 due to the August 2025 exit from Pooph-branded private-label sales. Excluding Pooph, non-consumer revenue grew 26% year over year for the first six months to $2,363,000.
Q2 2026 gross margin rose to 54% from 51% a year earlier, reflecting the loss of lower-margin private-label revenue and improved cost performance at ONM Environmental. Net loss widened to $4,000,000, with Clyra Medical contributing $2,375,000. BioLargo ended June 30, 2026 with $2,188,000 in cash, current assets of $3,499,000, current liabilities of $4,765,000, and a working capital deficit of $1,266,000.
About 86% of first-half 2026 capital was raised at subsidiaries, including $3,395,000 in Clyra debt and $487,000 in BioLargo Energy Technologies equity, versus $647,000 via BioLargo common stock. Operational highlights include ViaCLYR wound irrigation distribution agreements and revenue of $154,000 at Clyra, an October 2026 relaunch of CupriDyne-based consumer products under a company-owned brand, continued revenue at engineering unit BLEST ($1,888,000 in H1 2026), ongoing PFAS treatment at Lake Stockholm using the AEC system, and progress in the Cellinity long-duration energy storage program. Management outlined expected milestones over the next six to nine months and will host a stockholder town hall on September 10, 2026.
BioLargo (OTCQX:BLGO) reported that its patented Aqueous Electrostatic Concentrator (AEC) has treated more than two million gallons of PFAS-contaminated water over more than six months of commercial operation at the municipal drinking water facility in Lake Stockholm, New Jersey. Installed in January 2026, the system has consistently removed over 99% of PFAS, delivering effluent below all applicable New Jersey Department of Environmental Protection and U.S. EPA standards while generating significantly less PFAS-laden waste than conventional granular activated carbon systems, which can lower hazardous waste disposal and operating costs for the utility.
According to BioLargo, the Lake Stockholm site now functions as a commercial reference installation for prospective customers. The AEC is being monitored and tested under a 12‑month NJDEP and U.S. EPA program, and BioLargo plans to share third‑party performance data as it becomes available. The company is also pursuing additional municipal and industrial opportunities and views Lake Stockholm as a platform for its collaboration strategy with global water treatment company Aquatech.
BioLargo (OTCQX: BLGO) announced it has joined the New Jersey PFAS Partnership Innovation Consortium (NJ PFAS-PIC), a New Jersey Institute of Technology-led initiative launched in April 2026 to accelerate development, validation, and deployment of technologies for per- and polyfluoroalkyl substances (PFAS).
BioLargo also reported that Tonya Chandler, President of its subsidiary BioLargo Equipment Solutions & Technologies (BEST), has been appointed to the consortium’s Board of Directors, placing the company alongside NJIT, Princeton, Rutgers, Stevens, the New Jersey Department of Environmental Protection, major water utilities, and engineering and environmental firms in guiding PFAS detection, treatment, decontamination, management, and commercialization efforts.
According to BioLargo, membership in NJ PFAS-PIC builds on its prior PFAS work in New Jersey, including a commercial installation of its patented Aqueous Electrostatic Concentrator (AEC) at the Lake Stockholm municipal water facility, and creates opportunities for collaboration on technology demonstrations, regulatory validation, grant-funded research, and commercialization initiatives focused on advanced PFAS treatment solutions.
BioLargo (OTCQX:BLGO) announced that Tonya Chandler, President of subsidiary BioLargo Equipment Solutions & Technologies (BEST), will lead a seven-hour continuing education workshop, “PFAS 101 - Everything You Didn't Want to Know About PFAS,” at the 41st Annual Tri-State Seminar on Monday, August 3, 2026, at the South Point Hotel & Casino in Las Vegas.
This will be Chandler’s fourth consecutive year teaching at Tri-State, a major water industry event that drew nearly 4,800 participants in its 2025 edition. The PFAS 101 course is designed to give water professionals a practical, plain-language grounding in PFAS chemistry, health impacts, regulatory drivers, and treatment options, reflecting BioLargo’s field experience in PFAS collection, destruction, and disposal.
BioLargo (OTCQX:BLGO) announced that its PFAS treatment technology and leadership are featured in the Q1/Q2 2026 edition of The Disruptive Quarterly, titled “Water and Our Common Heritage: Facing the Challenge of Forever Chemicals.” The issue brings together environmental attorneys, researchers, industry innovators, and artists focused on protecting clean water from PFAS contamination.
According to BioLargo, the publication includes an article by Tonya Chandler, President of BioLargo Equipment Solutions and Technologies, and a transcript of CEO Dennis Calvert’s keynote on PFAS at the Norwegian Embassy in Washington, D.C. BioLargo’s PFAS platform centers on its patented Aqueous Electrostatic Concentrator (AEC), designed to rapidly and affordably remove and concentrate PFAS from contaminated water.
BioLargo (OTCQX:BLGO) announced the formation of subsidiary BioLargo CPG to relaunch CupriDyne®-based consumer pet products under a new, yet-to-be-named brand. The move follows the marketing success of CupriDyne products previously licensed to Pooph, which generated more than $125 million in pet-care sales.
BioLargo plans a digital-first strategy, selling direct-to-consumer and via online marketplaces such as Amazon, and intends to expand from pet odor control into broader household odor and cleaning products. According to Grand View Research, the U.S. pet odor control and clean-up market was about $6.47 billion in 2023, projected to reach $8.87 billion by 2030. Management highlights that BioLargo will now own the brand and control marketing and distribution.